Skip to main content

Table 2 The effect of combined magnesium and zinc supplementation on metabolic status in patients with T2DM and CHD

From: The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

Variables

Placebo group (n = 28)

Magnesium and zinc group (n = 27)

Difference in outcome measures between magnesium and zinc treatment groupsa

Baseline

Week 12

Baseline

Week 12

β (95% CI)

Pb

Magnesium (mg/dL)

1.84 Âħ 0.22

1.83 Âħ 0.25

1.94 Âħ 0.21

2.08 Âħ 0.22

0.15 (0.08, 0.22)

< 0.001

Zinc (Îĵg/dL)

93.3 Âħ 24.8

95.8 Âħ 25.9

98.1 Âħ 22.5

116.5 Âħ 21.5

16.21 (11.98, 20.44)

< 0.001

FPG (mg/dL)

123.7 Âħ 31.4

128.4 Âħ 32.7

119.2 Âħ 38.0

115.6 Âħ 28.7

−9.44 (−18.30, −0.57)

0.03

Insulin (ÎĵIU/mL)

13.8 Âħ 4.5

13.9 Âħ 4.4

12.9 Âħ 5.1

11.7 Âħ 4.9

−1.37 (−2.57, −0.18)

0.02

HOMA-IR

4.2 Âħ 1.8

4.2 Âħ 1.7

3.7 Âħ 1.7

3.4 Âħ 1.8

−0.36 (− 0.75, 0.02)

0.06

QUICKI

0.31 Âħ 0.02

0.31 Âħ 0.02

0.32 Âħ 0.02

0.32 Âħ 0.02

0.006 (−0.002, 0.01)

0.12

Triglycerides (mg/dL)

123.7 Âħ 50.7

124.9 Âħ 46.5

128.2 Âħ 55.7

134.6 Âħ 53.9

5.66 (−5.40, 16.73)

0.30

VLDL-cholesterol (mg/dL)

24.7 Âħ 10.1

24.9 Âħ 9.3

25.6 Âħ 11.1

26.9 Âħ 10.8

1.10 (−1.08, 3.34)

0.30

Total cholesterol (mg/dL)

147.3 Âħ 35.3

145.6 Âħ 31.0

137.1 Âħ 28.3

140.7 Âħ 32.5

3.72 (−5.26, 12.71)

0.41

LDL-cholesterol (mg/dL)

77.2 Âħ 29.5

76.6 Âħ 26.5

70.8 Âħ 22.4

71.6 Âħ 25.7

0.13 (−8.32, 8.59)

0.97

HDL-cholesterol (mg/dL)

45.3 Âħ 7.7

43.9 Âħ 7.0

40.6 Âħ 8.4

42.1 Âħ 8.2

2.09 (0.05, 4.13)

0.04

Total−/HDL-cholesterol ratio

3.3 Âħ 0.8

3.3 Âħ 0.7

3.4 Âħ 0.7

3.4 Âħ 0.8

−0.06 (−0.30, 0.17)

0.59

CRP (mg/L)

3.0 Âħ 1.0

3.2 Âħ 1.2

2.7 Âħ 1.7

2.1 Âħ 1.3

−0.85 (−1.26, − 0.45)

< 0.001

Total nitrite (Îĵmol/L)

49.8 Âħ 6.1

48.7 Âħ 6.1

43.7 Âħ 5.3

50.1 Âħ 6.5

5.13 (1.85, 8.41)

0.003

TAC (mmol/L)

898.4 Âħ 168.4

894.9 Âħ 178.9

940.9 Âħ 107.2

976.8 Âħ 105.3

43.44 (3.39, 83.50)

0.03

GSH (Îĵmol/L)

508.3 Âħ 72.9

524.9 Âħ 95.3

556.8 Âħ 92.9

578.2 Âħ 56.3

29.49 (−8.83, 67.82)

0.12

MDA (Îĵmol/L)

2.2 Âħ 0.6

2.2 Âħ 0.5

1.9 Âħ 0.4

1.8 Âħ 0.4

−0.15 (−0.32, 0.007)

0.05

BDI score

19.7 Âħ 5.8

19.6 Âħ 5.7

21.7 Âħ 4.7

19.6 Âħ 4.9

−1.66 (−3.32, −0.009)

0.04

BAI score

15.7 Âħ 4.3

14.1 Âħ 4.8

17.0 Âħ 5.3

14.0 Âħ 5.1

−1.30 (−2.43, −0.16)

0.02

  1. Data are mean Âħ SDs
  2. BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, CHD coronary heart disease, FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-estimated insulin resistance, CRP C-reactive protein, MDA malondialdehyde, QUICKI quantitative insulin sensitivity check index, T2DM type 2 diabetes, TAC total antioxidant capacity
  3. a”Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcome’s measures between treatment groups (magnesium and zinc group = 1 and placebo group = 0)]
  4. bObtained from multiple regression model (adjusted for baseline values of each biochemical variables)
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X